A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 834 participants.

Also called NCT03235050

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 834 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • MedImmune LLC Registry lists this organization as a collaborator
Registry
  • NCT NCT03235050
Other papers using this trial's data
  • Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study Diabetes care, 2021-06 DOI, PubMed 34016612, PMC8247525 PubMed links an erratum for this paper. Erratum: PMID 36228195 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, Germany, Mexico, Russia, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03235050. Randomized; triple masking; primary purpose treatment. Start 2017-08-02 (actual); primary completion 2018-05-03 (actual). Results posted on 2020-07-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
MEDI0382 low dose
Intervention (Drug)
MEDI0382 mid dose
Intervention (Drug)
MEDI0382 high dose
Intervention (Drug)
Placebo
Intervention (Drug)
Liraglutide
Lead sponsor
AstraZeneca (class: industry)
Collaborator
MedImmune LLC (class: industry)

Record details

Record id
cardio:ct-nct03235050
Content hash
45d7691987cc17ca131cb7c82b6ef896a15a25273711d2f4eea0b4268769e53c